AZD0305 alone or with other drugs for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that was diagnosed using standard criteria.
- You have already tried at least 1 to 3 previous treatments, depending on the part of the study.
- You are 18 years or older.
- Your cancer is measurable through blood or urine tests.
- Your organs and bone marrow are working well enough, per screening tests.
- You do not have certain other plasma cell disorders, uncontrolled infections, or previous stem cell transplant within 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
This trial tests a new drug (JNJ-79635322) combined with other treatments like daratumumab or pomalidomide for people with multiple myeloma. It aims to see if these combinations are safe and effective for newly diagnosed or previously treated patients.
This early-phase study tests how safe a new drug (CC-92480) is and how much it stays in the body, when given with other standard or study treatments. It’s for people whose multiple myeloma has come back or did not respond after prior therapy, with the goal of improving disease control.
This trial studies a new medicine called elranatamab combined with the chemotherapy drug cyclophosphamide for people with multiple myeloma that has returned or not responded to prior treatments. It may be a good option if you have aggressive or high-risk myeloma.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This trial tests a combination of three drugs (elranatamab, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to see if this treatment can lead to a very deep response (no detectable cancer cells) in the bone marrow.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.